Arcadia Biosciences (RKDA) Receivables (2014 - 2025)

Arcadia Biosciences has reported Receivables for 12 years, with the latest figure at $425000.0 in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 64.58% year-over-year to $425000.0; the trailing twelve-month figure through Dec 2025 stood at $425000.0 (down 64.58% YoY), and the FY2025 full-year result was $425000.0, down 64.58% from the prior year.
• Receivables for Q4 2025 stood at $425000.0, down from $831000.0 in the prior quarter.
• The five-year high for Receivables was $3.9 million in Q2 2022, with the low at $304000.0 in Q3 2023.
• Historically, Receivables has averaged $1.3 million across 5 years, with a median of $1.1 million in 2021.
• Annual changes were most pronounced in 2021 — Receivables jumped 289.54% — and 2023, when it sank 88.85%.
• Arcadia Biosciences' Receivables stood at $1.4 million in 2021, then fell by 12.41% to $1.2 million in 2022, then tumbled by 57.83% to $506000.0 in 2023, then jumped by 137.15% to $1.2 million in 2024, then tumbled by 64.58% to $425000.0 in 2025.
• The last three Receivables figures came in at $425000.0 (Q4 2025), $831000.0 (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.